



## **VIRTUAL– DEBATE**

Wednesday, **21 April 2021** a Debate from 13:00 to 14:00 hrs

### **The role of the Pharmaceutical Strategy in boosting patient access to new medicines**

The Pharmaceutical Strategy calls for equal access to safe, innovative and affordable therapies across the EU, but patients within and between EU member states currently face vastly different times to access new medicines. The wait can be as high as 1657 days in Estonia and as low as 127 days in Germany, after the European Medicines Agency's (EMA) approval. Poor access can have several root-causes, from the varying nature of national and regional health technology assessments (HTA) through to national pricing and reimbursement processes and limited national health budgets. The approval of a COVID-19 vaccine post EMA approval in just 24 hours instead of the allotted 67 days shows that faster access is possible. Join us on April 21st to discuss the role of the EU Pharmaceutical Strategy in driving faster and more equitable access for patients across the EU.

#### **Chair:**

Michael GAHLER MEP, President of the Kangaroo Group

#### **Speakers:**

Pierre DELSAUX, Deputy Director-General, DG Santé, European Commission

Nabil DAOUD, President of Lilly Spain, Portugal and Greece, Eli Lilly & Company

#### **Statement:**

Tomislav SOKOL MEP, EPP/Croatia, Member in the Committee on the Internal Market and Consumer Protection and Co-Chair of Interest Group on Equitable Access to Healthcare